Madhu Kumar
Stock Analyst at Goldman Sachs
(3.51)
# 918
Out of 4,479 analysts
138
Total ratings
52.69%
Success rate
16.77%
Average return
Main Sectors:
38 Stocks
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $105.09 | +60.81% | 7 | Jun 5, 2024 | |
FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $6.10 | -1.64% | 8 | Jan 26, 2024 | |
INFA Informatica | Maintains: Neutral | $23 → $26 | $30.51 | -14.78% | 5 | Dec 7, 2023 | |
UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $16.37 | +3.85% | 2 | Nov 10, 2023 | |
ALEC Alector | Initiates: Sell | $4 | $4.34 | -7.83% | 3 | Sep 25, 2023 | |
CERE Cerevel Therapeutics Holdings | Maintains: Neutral | $31 → $30 | $41.23 | -27.24% | 5 | May 23, 2023 | |
KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $177.61 | -12.73% | 12 | May 22, 2023 | |
CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $54.84 | -3.36% | 4 | May 5, 2023 | |
DSGN Design Therapeutics | Upgrades: Neutral | n/a | $3.20 | - | 3 | May 4, 2023 | |
ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $25.22 | +189.45% | 8 | May 3, 2023 | |
APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $34.98 | +303.09% | 9 | Apr 14, 2023 | |
SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $20.66 | +64.57% | 6 | Mar 1, 2023 | |
IOVA Iovance Biotherapeutics | Downgrades: Neutral | $20 → $6 | $7.73 | -22.38% | 6 | Dec 9, 2022 | |
ARCT Arcturus Therapeutics Holdings | Maintains: Sell | $8 → $14 | $21.48 | -34.82% | 6 | Nov 10, 2022 | |
DVAX Dynavax Technologies | Maintains: Buy | $24 → $21 | $11.08 | +89.53% | 2 | Nov 4, 2022 | |
EWTX Edgewise Therapeutics | Downgrades: Sell | $5 | $18.38 | -72.80% | 3 | Aug 25, 2022 | |
EDIT Editas Medicine | Maintains: Sell | $10 → $8 | $4.54 | +76.21% | 4 | May 24, 2022 | |
ARVN Arvinas | Maintains: Buy | $111 → $89 | $24.85 | +258.15% | 3 | May 24, 2022 | |
PASG Passage Bio | Downgrades: Neutral | $29 → $6 | $1.00 | +500.24% | 1 | Jan 19, 2022 | |
APLT Applied Therapeutics | Downgrades: Sell | n/a | $4.35 | - | 1 | Aug 27, 2021 | |
NTLA Intellia Therapeutics | Maintains: Neutral | n/a | $22.15 | - | 5 | Jun 23, 2021 | |
CLLS Cellectis | Upgrades: Outperform | n/a | $1.89 | - | 2 | Mar 16, 2021 | |
GRTS Gritstone bio | Downgrades: Underperform | n/a | $0.57 | - | 1 | Jan 20, 2021 | |
QURE uniQure | Upgrades: Outperform | n/a | $4.01 | - | 2 | Jul 31, 2020 | |
ABUS Arbutus Biopharma | Downgrades: Neutral | n/a | $3.13 | - | 8 | Jul 24, 2020 | |
APRE Aprea Therapeutics | Initiates: Outperform | n/a | $3.80 | - | 1 | Apr 21, 2020 | |
VIR Vir Biotechnology | Maintains: Underperform | n/a | $8.85 | - | 1 | Mar 27, 2020 | |
PIRS Pieris Pharmaceuticals | Upgrades: Outperform | $400 | $8.57 | +4,567.44% | 3 | Mar 13, 2020 | |
SRRK Scholar Rock Holding | Initiates: Outperform | n/a | $7.63 | - | 1 | Mar 12, 2020 | |
LPTX Leap Therapeutics | Initiates: Outperform | n/a | $1.69 | - | 1 | Feb 11, 2020 | |
EYPT EyePoint Pharmaceuticals | Maintains: Buy | n/a | $8.01 | - | 1 | Oct 16, 2018 | |
ASMB Assembly Biosciences | Upgrades: Buy | $504 | $13.35 | +3,675.28% | 3 | Oct 8, 2018 | |
ALNY Alnylam Pharmaceuticals | Maintains: Buy | n/a | $247.61 | - | 2 | Aug 13, 2018 | |
RGLS Regulus Therapeutics | Maintains: Neutral | n/a | $1.76 | - | 3 | Jul 6, 2018 | |
IFRX InflaRx | Initiates: Buy | n/a | $1.73 | - | 1 | Feb 8, 2018 | |
AKTX Akari Therapeutics, | Initiates: Neutral | n/a | $3.10 | - | 3 | Feb 8, 2018 | |
TGTX TG Therapeutics | Reinstates: Buy | n/a | $18.31 | - | 1 | Dec 1, 2017 | |
CRSP CRISPR Therapeutics AG | Initiates: Buy | n/a | $53.12 | - | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $105.09
Upside: +60.81%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $6.10
Upside: -1.64%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $30.51
Upside: -14.78%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $16.37
Upside: +3.85%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $4.34
Upside: -7.83%
Cerevel Therapeutics Holdings
May 23, 2023
Maintains: Neutral
Price Target: $31 → $30
Current: $41.23
Upside: -27.24%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $177.61
Upside: -12.73%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $54.84
Upside: -3.36%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.20
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $25.22
Upside: +189.45%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $34.98
Upside: +303.09%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $20.66
Upside: +64.57%
Iovance Biotherapeutics
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $7.73
Upside: -22.38%
Arcturus Therapeutics Holdings
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $21.48
Upside: -34.82%
Dynavax Technologies
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $11.08
Upside: +89.53%
Edgewise Therapeutics
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $18.38
Upside: -72.80%
Editas Medicine
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $4.54
Upside: +76.21%
Arvinas
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $24.85
Upside: +258.15%
Passage Bio
Jan 19, 2022
Downgrades: Neutral
Price Target: $29 → $6
Current: $1.00
Upside: +500.24%
Applied Therapeutics
Aug 27, 2021
Downgrades: Sell
Price Target: n/a
Current: $4.35
Upside: -
Intellia Therapeutics
Jun 23, 2021
Maintains: Neutral
Price Target: n/a
Current: $22.15
Upside: -
Cellectis
Mar 16, 2021
Upgrades: Outperform
Price Target: n/a
Current: $1.89
Upside: -
Gritstone bio
Jan 20, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.57
Upside: -
uniQure
Jul 31, 2020
Upgrades: Outperform
Price Target: n/a
Current: $4.01
Upside: -
Arbutus Biopharma
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.13
Upside: -
Aprea Therapeutics
Apr 21, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.80
Upside: -
Vir Biotechnology
Mar 27, 2020
Maintains: Underperform
Price Target: n/a
Current: $8.85
Upside: -
Pieris Pharmaceuticals
Mar 13, 2020
Upgrades: Outperform
Price Target: $400
Current: $8.57
Upside: +4,567.44%
Scholar Rock Holding
Mar 12, 2020
Initiates: Outperform
Price Target: n/a
Current: $7.63
Upside: -
Leap Therapeutics
Feb 11, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.69
Upside: -
EyePoint Pharmaceuticals
Oct 16, 2018
Maintains: Buy
Price Target: n/a
Current: $8.01
Upside: -
Assembly Biosciences
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $13.35
Upside: +3,675.28%
Alnylam Pharmaceuticals
Aug 13, 2018
Maintains: Buy
Price Target: n/a
Current: $247.61
Upside: -
Regulus Therapeutics
Jul 6, 2018
Maintains: Neutral
Price Target: n/a
Current: $1.76
Upside: -
InflaRx
Feb 8, 2018
Initiates: Buy
Price Target: n/a
Current: $1.73
Upside: -
Akari Therapeutics,
Feb 8, 2018
Initiates: Neutral
Price Target: n/a
Current: $3.10
Upside: -
TG Therapeutics
Dec 1, 2017
Reinstates: Buy
Price Target: n/a
Current: $18.31
Upside: -
CRISPR Therapeutics AG
Mar 28, 2017
Initiates: Buy
Price Target: n/a
Current: $53.12
Upside: -